PAVmed Inc (PAVMZ) 是一家上市公司 属于 医疗保健 板块，经营于 Medical - Devices 行业. 公司总部位于 New York City, DE, 美国. 现任CEO为 Lishan Aklog.
PAVMZ 拥有 IPO日期为 2018-04-10, 39 名全职员工, 在 NASDAQ Capital Marke, 市值为 $11.92K.
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
